• AZ505 SMYD2 Inhibitor: Protocol-Driven Advances in Epigeneti

  2026-04-30

  AZ505, a potent and selective SMYD2 inhibitor, empowers researchers to dissect epigenetic mechanisms and disease pathways with high specificity. This guide distills actionable workflows, troubleshooting insights, and key innovations—enabling robust interrogation of SMYD2-dependent biology in cancer and renal fibrosis models.

• Ruxolitinib Triggers Apoptosis and Pyroptosis in ATC via DRP

  2026-04-30

  This study demonstrates that Ruxolitinib phosphate (INCB018424) induces both apoptosis and GSDME-mediated pyroptosis in anaplastic thyroid carcinoma (ATC) by inhibiting DRP1-mediated mitochondrial fission through suppression of JAK1/2-STAT3 signaling. These findings reveal a novel mechanism of mitochondrial dynamics regulation in ATC and identify a promising therapeutic avenue for this aggressive malignancy.

• L-NAME Hydrochloride: Optimizing NOS Inhibition for Vascular

  2026-04-29

  L-NAME Hydrochloride (NG-nitro-L-arginine methyl ester) stands as a proven tool for dissecting nitric oxide signaling and vascular tone regulation in both cellular and animal models. Here, we provide actionable workflows, troubleshooting insights, and direct translation of the latest anti-inflammatory mechanistic research to elevate your cardiovascular disease model experiments.

• Decitabine (5-Aza-2'-deoxycytidine) in Cancer Epigenetics Re

  2026-04-29

  Decitabine (5-Aza-2'-deoxycytidine) is a cornerstone for translational cancer epigenetics, enabling precise DNA hypomethylation and robust tumor suppressor gene reactivation in both hematopoietic and solid tumor models. This article details optimized workflows, data-driven troubleshooting, and key innovations from foundational toxicology studies, empowering researchers to maximize reproducibility and biological insight.

• SMYD2 Inhibition Mitigates Renal Fibrosis in Cisplatin-Induc

  2026-04-28

  This study demonstrates that pharmacological inhibition of SMYD2, specifically using AZ505, can protect against renal fibrosis and inflammation in a cisplatin-induced chronic kidney disease (CKD) model. The findings highlight SMYD2 as a promising therapeutic target for CKD, underscoring the translational potential of substrate-competitive SMYD2 inhibitors in renal and epigenetic research.

• CHIR-99021 (CT99021): GSK-3 Inhibition for Organoid Innovati

  2026-04-28

  Explore how CHIR-99021 (CT99021) enables next-generation stem cell and organoid research, with mechanistic clarity and translational strategy. This article synthesizes current best practices, validated data, and cutting-edge insights from multiendodermal organ atlas research, providing a roadmap for researchers seeking reproducible, high-impact outcomes in developmental biology and regenerative medicine.

• Nuclear Export Inhibition Synergy in Basal-like TNBC Models

  2026-04-27

  This study identifies KPT-330 (Selinexor), a selective nuclear export inhibitor, as a synergistic agent in combination therapies for triple-negative breast cancer (TNBC) preclinical models. By integrating high-throughput drug screening with patient-derived xenografts and transcriptomic analysis, the research highlights XPO1 overexpression as a targetable vulnerability in basal-like TNBC, informing future experimental designs.

• AZ505 SMYD2 Inhibitor: Precision Tools for Epigenetic and Ca

  2026-04-27

  AZ505 stands out as a highly selective SMYD2 inhibitor, enabling rigorous dissection of histone methylation and non-histone signaling in disease models. Its proven efficacy in renal fibrosis and oncology workflows offers researchers robust, reproducible results where SMYD2 activity is pivotal.

• Ruxolitinib Phosphate in Mitochondrial Dynamics & Oncology R

  2026-04-26

  Explore the unique role of Ruxolitinib phosphate (INCB018424) in modulating mitochondrial fission and inducing programmed cell death in aggressive cancers. This in-depth article offers fresh insights beyond standard JAK/STAT pathway inhibition, revealing new opportunities for oncology and disease modeling research.

• RG7388 and the p53-MDM2 Axis: Strategic Leverage for Transla

  2026-04-25

  This thought-leadership article provides an advanced synthesis of mechanistic insight and translational strategy revolving around RG7388 (a potent, selective oral MDM2 antagonist) and its role in p53 pathway activation, cancer cell apoptosis induction, and therapy sensitization. By integrating recent biomarker discoveries—specifically the MDM1-p53-apoptosis axis in chemoradiotherapy sensitivity—this piece delivers actionable guidance for translational researchers, highlighting experimental best practices, clinical implications, and a differentiated, forward-looking perspective that builds on but goes beyond standard product information.

• Cambinol: Bridging SIRT1/2 Inhibition to CNS Injury Repair

  2026-04-24

  This thought-leadership article illuminates the emerging intersection between SIRT1/2 inhibition and central nervous system (CNS) injury research, centering on the multifaceted capabilities of SIRT1/2 Inhibitor IV (cambinol). Drawing from recent advances that link SIRT1-regulated lactylation to astrocyte polarization post-injury, we synthesize mechanistic insights, translational workflows, and evidence-driven protocols. The discussion situates cambinol within the evolving landscape of metabolic-epigenetic therapeutics, offering actionable guidance to researchers aiming to leverage its dual relevance in oncology and CNS repair.

• BFH772 (VEGFR2 inhibitor): Technical Guide and Protocol Para

  2026-04-24

  BFH772 is a potent, selective VEGFR2 inhibitor optimized for research applications that require precise modulation of VEGFR2-mediated angiogenesis, particularly in tumor models. It should not be used in workflows demanding water-soluble compounds or broad-spectrum kinase inhibition, given its defined solubility and selectivity characteristics.

• Cell Cycle Assay Kit (K2263): DNA Content Analysis & Apoptos

  2026-04-23

  The Cell Cycle Assay Kit (Catalog No. K2263) enables precise analysis of cell cycle phases G0/G1, S, and G2/M via propidium iodide DNA staining. Its robust, reproducible performance supports advanced cell cycle progression analysis and apoptosis detection by sub-G1 peak in cancer research. The kit is validated for high-specificity flow cytometry applications.

• Wallichinine Overcomes ABCB1-Mediated Multidrug Resistance i

  2026-04-23

  The referenced study demonstrates that wallichinine, a natural compound from Piper wallichii, effectively reverses multidrug resistance (MDR) mediated by ABCB1 in cancer cells. By blocking ABCB1 drug efflux and enhancing chemotherapeutic efficacy, this research offers promising directions for overcoming MDR in oncology.

• GKT137831: Dual NADPH Oxidase Nox1/Nox4 Inhibitor in Redox R

  2026-04-22

  GKT137831 sets a new standard as a selective dual NADPH oxidase Nox1/Nox4 inhibitor for oxidative stress and fibrosis modeling. Its high specificity and translational impact empower vascular, liver, and metabolic disease workflows, with reliable protocols and troubleshooting insights for reproducible results.

16751 records 1/1117 page Next 12345 下5页 Last page